This company listing is no longer active
MR4 Stock Overview
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Meridian Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.90 |
| 52 Week High | US$33.18 |
| 52 Week Low | US$18.52 |
| Beta | 0.23 |
| 1 Month Change | 0.26% |
| 3 Month Change | -5.99% |
| 1 Year Change | 63.75% |
| 3 Year Change | 312.00% |
| 5 Year Change | 160.98% |
| Change since IPO | 1,254.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| MR4 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.9% | -5.0% | -2.0% |
| 1Y | 63.8% | -13.6% | -0.3% |
Return vs Industry: MR4 exceeded the German Medical Equipment industry which returned -15.8% over the past year.
Return vs Market: MR4 exceeded the German Market which returned -11.9% over the past year.
Price Volatility
| MR4 volatility | |
|---|---|
| MR4 Average Weekly Movement | 2.3% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MR4 has not had significant price volatility in the past 3 months.
Volatility Over Time: MR4's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 704 | Jack Kenny | www.meridianbioscience.com |
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT!
Meridian Bioscience, Inc. Fundamentals Summary
| MR4 fundamental statistics | |
|---|---|
| Market cap | €1.38b |
| Earnings (TTM) | €39.06m |
| Revenue (TTM) | €306.34m |
35.2x
P/E Ratio4.5x
P/S RatioIs MR4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MR4 income statement (TTM) | |
|---|---|
| Revenue | US$333.02m |
| Cost of Revenue | US$144.66m |
| Gross Profit | US$188.36m |
| Other Expenses | US$145.90m |
| Earnings | US$42.46m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.96 |
| Gross Margin | 56.56% |
| Net Profit Margin | 12.75% |
| Debt/Equity Ratio | 6.8% |
How did MR4 perform over the long term?
See historical performance and comparison